Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + cladribine + cytarabine + filgrastim + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intrathecal, Oral
01
Overview
This is a combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), cladribine (a purine nucleoside analog), cytarabine (a pyrimidine analog), mitoxantrone (an antitumor antibiotic), and filgrastim (a granulocyte colony-stimulating factor). The combination is likely used in the treatment of hematological malignancies. Clinical trials have shown that cladribine combined with cyclophosphamide and mitoxantrone (CMC) induces higher complete response rates in chronic lymphocytic leukemia compared to cladribine alone, though with increased toxicity including neutropenia and infections.
02
Targets
DNARNR (Ribonucleotide reductase)TOP2A (DNA topoisomerase II)POLA1 (DNA polymerase alpha)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on cyclophosphamide + cladribine + cytarabine + filgrastim + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + cladribine + cytarabine + filgrastim + mitoxantrone.